Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.

Alzheimer’s drug Leqembi (lecanemab) is reportedly offering hope for patients in the early stages of the disease despite it ...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...

Eisai Co., Ltd. announced today that it has acquired its own shares based on Article 40 of its Articles of Incorporation pursuant to the provisions of Article 459, paragraph 1 of the Companies Act.

GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Acral Lentiginous Melanoma.

Foscenvivint is under development for the treatment of HCV or HBV or NASH-induced decompensated cirrhosis, leukemia such as acute myeloid leukemia (AML), neuroendocrine tumors, ch ...

Durable Clinical Benefit Observed Beyond a Year on Treatment in Heavily Pre-Treated PatientsBoston (September 16, 2024) — Allarity ...

PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the ...

Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...